Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Node; Prostate × durvalumab × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 22 Lung Neoplasms 11 Carcinoma, Hepatocellular 11 Small Cell Lung Carcinoma 9 Liver Neoplasms 6 Biliary Tract Neoplasms 6 Neoplasm Metastasis 4 Urinary Bladder Neoplasms 3 Pancreatic Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 3 Neoplasms 3 Carcinoma, Transitional Cell 3 Breast Neoplasms 3 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Unresectable Hepatocellular Carcinoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Malignancies 1 Skin Neoplasms 1 Resectable Intrahepatic Cholangiocarcinoma 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Platinum-Resistant Lung Small Cell Carcinoma 1 Pathologic Complete Response 1 Osteosarcoma 1 Node; Prostate 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1

Interventions

durvalumab 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03795207 2026-03-31

POSTCARD

Institut Cancerologie de l'Ouest

Phase 2 Active not recruiting

Node; Prostate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡